Cargando…

Virologic response and breakthrough in chronic hepatitis B Egyptian patients receiving lamivudine therapy

BACKGROUND: Lamivudine monotherapy is effective in suppressing hepatitis B virus (HBV) replication to undetectable levels by PCR, in ameliorating liver disease and to some extent in achieving HBsAg seroconversion. This study aimed at assessing the virological and biochemical responses as well as bre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ismail, Sohair, Hafez, Hanan Abdel, Darweesh, Samar K., Kamal, Kamal Hassan, Esmat, Gamal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hellenic Society of Gastroenterology 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188937/ https://www.ncbi.nlm.nih.gov/pubmed/25331321

Ejemplares similares

Accurate Prediction of Advanced Liver Fibrosis Using the Decision Tree Learning Algorithm in Chronic Hepatitis C Egyptian Patients
por: Hashem, Somaya, et al.
Publicado: (2016)

Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients
por: Jung, Young Kul, et al.
Publicado: (2011)

Lamivudine Resistance and Precore Variants in Iranian Patients With Chronic Hepatitis B: Correlation With Virological and Clinical Features
por: Poortahmasebi, Vahdat, et al.
Publicado: (2015)

Virovore: A Breakthrough in Virology
por: Sultana, Qamar, et al.
Publicado: (2023)

Regulatory and activated effector T cells in chronic hepatitis C virus: Relation to autoimmunity
por: Fouad, Hanan, et al.
Publicado: (2016)

Efficacy of Lamivudine or Entecavir against Virological Rebound after Achieving HBV DNA Negativity in Chronic Hepatitis B Patients
por: Miyauchi, Tomoo, et al.
Publicado: (2013)

Whole-genome sequencing of human Pegivirus variant from an Egyptian patient co-infected with hepatitis C virus: a case report
por: Soliman, Hany K., et al.
Publicado: (2019)

Predictors of severity and development of critical illness of Egyptian COVID-19 patients: A multicenter study
por: Omran, Dalia, et al.
Publicado: (2021)

Apelin Serum Level in Egyptian Patients with Chronic Hepatitis C
por: El-Mesallamy, Hala O., et al.
Publicado: (2011)

Evaluation of Nitric Oxide (NO) Levels in Hepatitis C Virus (HCV) Infection: Relationship to Schistosomiasis and Liver Cirrhosis among Egyptian Patients
por: Hassan, Mahmoud Ismail, et al.
Publicado: (2002)

Validation of Hepa-index as a non-invasive biomarkers panel for assessment of hepatic fibrosis in Egyptians with chronic hepatitis C
por: Alboraie, Mohamed, et al.
Publicado: (2017)

Incidence of hepatitis C virus infection among people living with HIV: An Egyptian cohort study
por: Elrashdy, Fatma, et al.
Publicado: (2022)

Adherence to Medication Is a More Important Contributor to Viral Breakthrough in Chronic Hepatitis B Patients Treated with Entecavir Than in Those with Lamivudine
por: Kamezaki, Hidehiro, et al.
Publicado: (2013)

Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir
por: Suzuki, Fumitaka, et al.
Publicado: (2014)

Association of virological breakthrough and clinical outcomes in entecavir-treated HBeAg-positive chronic hepatitis B
por: Huang, Yi-Jie, et al.
Publicado: (2019)

Lamivudine Concentration in Hair and Prediction of Virologic Failure and Drug Resistance among HIV Patients Receiving Free ART in China
por: Yan, Jing, et al.
Publicado: (2016)

Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression
por: Carbone, Alessia, et al.
Publicado: (2014)

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2017)

HBV quasispecies composition in Lamivudine-failed chronic hepatitis B patients and its influence on virological response to Tenofovir-based rescue therapy
por: Banerjee, Priyanka, et al.
Publicado: (2017)

Analysis of clinical and virologic features in Hepatitis B e Antigen (HbeAg)-negative and HbeAg-positive Egyptian chronic hepatitis B patients
por: Fouad, Rabab, et al.
Publicado: (2020)

Genetic profile of Egyptian hepatocellular-carcinoma associated with hepatitis C virus Genotype 4 by 15 K cDNA microarray: Preliminary study
por: Zekri, Abdel-Rahman N, et al.
Publicado: (2008)

Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
por: Park, Chan Ho, et al.
Publicado: (2016)

Lamivudine Therapy for Korean Children with Chronic Hepatitis B
por: Koh, Hong, et al.
Publicado: (2007)

Association of HCV with diabetes mellitus: an Egyptian case-control study
por: Elhawary, Eman I, et al.
Publicado: (2011)

A Polymorphism in the Microsomal Triglyceride Transfer Protein Can Predict the Response to Antiviral Therapy in Egyptian Patients with Chronic Hepatitis C Virus Genotype 4 Infection
por: Saad, Yasmin, et al.
Publicado: (2014)

On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B
por: Huang, Yi-Jie, et al.
Publicado: (2017)

Hepatitis B virus (HBV) genotypes in Egyptian pediatric cancer patients with acute and chronic active HBV infection
por: Zekri, Abdel-Rahman N, et al.
Publicado: (2007)

Sustained virological and biochemical responses to lamivudine and adefovir dipivoxil combination in a chronic hepatitis B infection despite mutations conferring resistance to both drugs
por: Larrat, Sylvie, et al.
Publicado: (2008)

Efficacy of Lamivudine or Entecavir on Acute Exacerbation of Chronic Hepatitis B
por: Kanda, Tatsuo, et al.
Publicado: (2011)

Entecavir and lamivudine therapy for severe acute chronic hepatitis B
por: LIU, CHANGHONG, et al.
Publicado: (2013)

High Dose of Lamivudine and Resistance in Patients with Chronic Hepatitis B
por: Wani, Hamid Ullah, et al.
Publicado: (2014)

High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial
por: Alexander, George, et al.
Publicado: (2005)

Hemochromatosis Gene Polymorphism as a Predictor of Sustained Virological Response to Antiviral Treatment in Egyptian Chronic Hepatitis C Patients
por: I Mehrez, Mai, et al.
Publicado: (2017)

Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study
por: Llibre, Josep M., et al.
Publicado: (2016)

Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment
por: Wang, Zhao, et al.
Publicado: (2011)

Long-Term Outcomes and Dynamics of Mutants Associated with Lamivudine-Adefovir Rescue Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B
por: Kim, Jihyun, et al.
Publicado: (2015)

The Attitude of Egyptian Patients with Autoimmune and Rheumatic Diseases towards Telemedicine
por: Tharwat, Samar, et al.
Publicado: (2023)

Combination therapy of lamivudine and adefovir in Japanese patients with chronic hepatitis B
por: Shakado, Satoshi, et al.
Publicado: (2008)

Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B
por: Chao, Daniel C, et al.
Publicado: (2013)

Lamivudine therapy for chronic hepatitis B in children: a meta-analysis
por: Luo, Aoran, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m3fk2nbkdg24d2f05314enlg5f